Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report

Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report

Source: 
Fierce Pharma
snippet: 

In 2026—the first year Medicare’s price negotiations are set to start under the IRA—the top drugs expected to fall victim to discussions include blood thinners Eliquis from Bristol Myers Squibb and Xarelto from Johnson & Johnson. Oral diabetes drugs such as Merck's Januvia and Boehringer Ingelheim and Eli Lilly's Jardiance may also face negotiations during the first year, the journal says.